IBT welcomes Anna Olsson as Director of Clinical Development.

Anna has extensive experience in leading and coordinating clinical programs for pharmaceutical companies such as Sobi and AstraZeneca as well as the clinical research organization Quintiles.

Anna’s experience from leading clinical trials, including pivotal trials in premature infants, will be a valuable contribution to IBT during the planned Phase III clinical trial.